カテゴリ： GlobalData, アメリカ, 企業調査

Johnson & Johnson (JNJ)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010872
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：663
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Johnson & Johnson (J&J) engages in the research and development, manufacture and sale of a range of healthcare products. Its primary focus is on the development of products related to human health and well-being. The company provides pharmaceuticals in immunology, cancer, neuroscience, infectious, cardiovascular and metabolic diseases areas; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and consumer products through retail outlets and distributors. The company provides its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 14
List of Figures 21
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 22
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 23
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 24
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 25
Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 27
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 29
Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 63
Asset Purchase 63
Janssen Pharma Acquires CERC-501 from Cerecor 63
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 64
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 65
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 66
J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 67
Venture Financing 69
On Target Laboratories Raises USD40 Million in Financing 69
Fusion Pharma Raises Additional USD17 Million in Series A Financing 70
XW Labs Raises USD17.5 Million in Series B Financing 72
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 73
E-scape Bio Raises Additional USD8 Million in Series A Financing 75
DayTwo Secures USD12 Million in Series A Funding 76
DayTwo Raises USD12 Million in Series A Financing 77
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 78
Biomx Raises USD24 Million in Series A Venture Financing 79
Pulmocide Raises USD30.4 Million in Series B Financing 80
Grail Raises USD914 Million in First Tranche of Series B Financing 82
Fusion Pharma Raises USD19 Million in Series A Financing 84
SuperX Raises USD11 Million in Series A Financing 85
Caelus Health Raises USD2.7 Million in Series A Financing 86
ApoGen Biotech Raises USD7 Million in Series A Financing 87
ReVision Optics Raises USD32 Million in Venture Financing 88
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 90
V-Wave Raises USD28 Million in Venture Financing 91
Lodo Therapeutics Raises USD17 Million in Series A Financing 92
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 94
Petra Pharma Raises USD48 Million in Series A Financing 95
Protekt Therapeutics Raises More Than USD2 Million in Financing 97
Navitor Pharma Raises USD33 Million in Series B Financing 98
First Aid Shot Therapy Raises USD24 Million in Series C Financing 100
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 101
Asceneuron Raises USD30.6 Million in Series A Financing 102
Merus Raises USD46.4 Million in First Tranche of Series C Financing 104
E-scape Bio Raises USD55 Million in Series A Financing 106
Alligator Bioscience to Raise Funds through Venture Financing 107
Protagonist Therapeutics Raises USD40 Million in Series C Financing 108
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 110
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 112
La Lumiere Raises USD20 Million in Series B Venture Financing 113
Tetra Discovery Raises Funds through Venture Financing 114
XW Labs Raises USD5.5 Million in Series A Financing 115
Inivata Raises USD6.5 Million in Venture Financing 116
Inviata Raises USD6.5 Million in Venture Financing 117
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 118
Ascelegen Therapeutics Raises Funds through Venture Financing 119
Padlock Therapeutics Raises Funds through Series A Financing 120
Navitor Pharma Raises USD24 Million in Series A Financing 121
Aduro BioTech Raises USD55 Million in Series C Financing 123
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 124
Assembly Pharma Raises Funds Through Seed Financing 125
Alios BioPharma Raises US$41 Million In Series B Venture Financing 126
Covagen Raises US$50.3 Million In Series B Financing 127
Novira Therapeutics Raises US$28 Million In Series A Financing 129
SutroVax Raises Funds Through Initial Financing Round 131
TopiVert Raises USD28 Million in Venture Financing 132
TopiVert Raises US$7.4 Million In Venture Financing 133
Pulmocide Raises US$27.4 Million In Series A Financing 135
Biocartis Raises US$40.5 Million In Series E Financing 137
Merus Raises US$42 Million In Extended Series B Financing 139
Rodin Therapeutics Raises Funds Through Seed Financing 141
Vedanta Biosciences Raises Funds Through Venture Financing 142
XO1 Raises USD11 Million in Venture Financing 143
X01 Raises US$11 Million In Series A Financing 144
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 145
Novira Therapeutics Secures USD25 Million in Venture Funding 147
Aquinox Pharma Raises US$18 Million In Series C Financing 148
Biocartis Raises US$44.7 Million In Series D Financing 149
Genocea Biosciences Raises US$30 Million In Series C Financing 151
Aragon Pharma Raises US$50 Million In Series D Financing 153
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 154
Celladon Raises Additional US$10 Million In Series D Financing 156
Direct Flow Medical Secures USD0.28 Million in Venture Funding 158
Coherex Medical Secures USD16.5 Million in Venture Funding 159
Aragon Pharma Raises US$42 Million In Series C Financing 160
Biocartis Secures US$96 Million In Series C Financing Round 161
Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 163
Spinal Modulation Secures US$30 Million In Series D Financing 164
23andMe Raises Additional USD9 Million in Series C Financing 166
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 167
Private Equity 169
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 169
Water Street Healthcare Partners Acquires OraPharma 170
Partnerships 171
Janssen Amends Licensing Agreement with Gilead for STR 171
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 172
Genomic Health Enters into Research Agreement with Janssen Pharma 173
BioMed X Enters into Agreement with Janssen Research & Development 174
Cerveau Technologies Enters into Agreement with Janssen Pharma 175
Janssen Research & Development Enters into Agreement with U.S. Department of Health 176
Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 177
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 178
Proteros biostructures Enters into Research Agreement with Janssen Biotech 179
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 180
Idorsia and Janssen Biotech to Enter into option Agreement 181
Monash University Enters into Research Agreement with Janssen Biotech 182
Phagelux Enters into Agreement with Johnson & Johnson Consumer 183
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 184
PeptiDream Enters into Agreement with Janssen Pharma 185
Janssen Pharma Enters into Partnership with Premier 186
Renova Therapeutics Enters into Agreement with Janssen Pharma 187
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 188
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 189
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 190
Janssen Research & Development Enters into Agreement with ChemDiv 191
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 192
Enamine Expands Agreement with Actelion 193
Karolinska Institutet Partners with Johnson & Johnson Companies 194
Janssen Biotech Enters into Partnership with Bristol-Myers 195
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 196
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 197
Janssen Pharma Enters into Partnership with Bird Rock Bio 198
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 199
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 200
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 201
HitGen Enters into Agreement with Janssen Biotech 202
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 203
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 204
Philogen Enters into Co-Development Agreement with Janssen Biotech 205
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 206
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 207
Amyris Enters into Research Agreement with Janssen Biotech 208
Janssen Research & Development Enters into Agreement with Genentech 209
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 210
DiamiR Enters into Research Agreement with Janssen Pharma 211
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 212
Janssen Biotech Enters into Agreement with HUB foundation 213
Janssen Pharma Enters into Agreement with University of Pennsylvania 214
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 215
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 216
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 217
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 218
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 219
Janssen Pharma Enters into Agreement with University of California, San Diego 220
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 221
Johnson & Johnson Consumer Enters into Agreement with BioMed X 222
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 223
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 224
Janssen Biotech Enters into Agreement with Eureka Therapeutics 225
Intrexon Enters into Research Agreement with Janssen Pharma 226
Cypralis Enters into Research Agreement with Janssen Pharma 227
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 228
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 229
SynAging Extends Agreement with Actelion Pharma 230
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 231
Nuevolution Enters into Discovery Agreement with Janssen Biotech 232
enGene Enters into Agreement with Janssen Biotech 233
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 234
BlinkBio Enters into Discovery Agreement with Janssen Pharma 235
UbiVac Enters into Agreement with Janssen Biotech 236
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 237
Nextera Enters into Research Agreement with Janssen Biotech 238
Handok Enters into Agreement with Actelion Pharmaceuticals 239
Actelion Forms Joint Venture with Max Planck Society 240
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 241
Janssen Cilag Enters into Agreement with UniQuest 242
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 243
Janssen Biotech Enters into Research Agreement with Emulate 244
Johnson & Johnson Innovation Partners with Lead Discovery Center 245
NeurOp Enters into Research Agreement with Janssen Pharma 246
AC Immune Enters into Research Agreement with Janssen Pharma 247
X-Chem Expands Agreement with Janssen Biotech 248
Vectura Enters into Development and License Agreement with Janssen Biotech 249
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 250
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 251
Atreca Enters into Research Agreement with Janssen Biotech 252
Vaccinex Enters into Research Agreement with Janssen Research & Development 253
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 254
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 255
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 256
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 257
Alector Enters Into Research Agreement With Janssen Pharma 258
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 259
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 260
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 261
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 262
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 263
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 264
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 265
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 266
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 267
Open Monoclonal Expands Agreement with CNA Development 268
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 269
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 270
ex scientia Enters into Agreement with Janssen Research & Development 272
Mellitech Enters into Agreement with Janssen Pharma 273
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 274
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 275
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 276
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 277
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 278
Beactica Enters Into Research Agreement With Janssen Research & Development 279
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 280
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 281
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 282
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 283
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 284
Dendright Enters Into Research Agreement With Janssen-Cilag 285
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 286
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 287
Molecular Partners Enters Into Research Agreement With Janssen Biotech 288
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 289
Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 290
Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 291
Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 292
ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 293
Synthes Enters Into Co-Development Agreement With Eli Lilly 294
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 295
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 296
Beactica Enters Into An Agreement With Janssen 297
Merck Amends Distribution Agreement With Johnson & Johnson 298
Medivir Enters Into Collaboration With Janssen Pharmaceutica 300
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 301
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 302
Stereotaxis Amends Co-Development Agreement With Biosense Webster 303
Licensing Agreements 304
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 304
Janssen Biotech Enters into Licensing Agreement with Zymeworks 305
Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 306
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 307
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 309
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 310
Pulmatrix Enters into Licensing Agreement with RespiVert 311
Janssen Biotech Enters into Licensing Agreement with Trianni 312
Janssen Biotech Enters into Licensing Agreement with Ablexis 313
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 314
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 316
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 317
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 318
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 319
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 320
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 321
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 322
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 324
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 325
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 326
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 327
Janssen Biotech Enters into Licensing agreement with Tesaro 328
ViaCyte Enters into Licensing Agreement with Janssen Biotech 329
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 330
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 331
Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 332
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 333
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 334
AC Immune Enters into Licensing Agreement with Janssen Pharma 335
Janssen Expands Licensing Agreement with Gilead 336
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 337
Kura Oncology Amends Licensing Agreement with Janssen Pharma 339
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 341
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 342
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 344
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 345
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 347
XO1 Enters into Licensing Agreement with Cambridge Enterprise 348
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 349
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 350
Depomed Enters Into Licensing Agreement With Janssen Pharma 352
Genmab Expands Licensing Agreement With Janssen Biotech 353
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 354
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 355
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 356
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 357
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 358
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 359
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 360
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 361
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 362
Poseida Therapeutics Enters into Licensing Agreement with Janssen 363
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 364
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 365
Gour Medical Enters into Licensing Agreement with Actelion Pharma 366
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 367
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 368
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 369
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 370
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 371
AB-Biotics Enters into Licensing Agreement with Cilag 372
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 373
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 374
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 375
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 376
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 377
Janssen Pharma Enters into Licensing Agreement with BiocerOX 379
Orion Enters Into Licensing Agreement With Janssen Pharma 380
CSL Enters Into Licensing Agreement With Janssen For CSL-362 381
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 382
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 384
Intravacc Enters into Licensing Agreement with Crucell Holland 385
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 386
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 387
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 388
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 389
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 390
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 391
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 392
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 393
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 394
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 395
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 396
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 397
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 398
Shionogi Enters Into Licensing Agreement With Janssen Pharma 400
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 401
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 403
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 404
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 405
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 407
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 408
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 410
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 411
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 412
GlaxoSmithKline Enters into Licensing Agreement with Janssen Biologics 413
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 414
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 415
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 416
Topivert Enters into Licensing Agreement with RespiVert 418
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 419
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 420
Alios BioPharma Enters Into Licensing Agreement With Versitech 421
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 422
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 423
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 424
Isconova Expands Licensing Agreement With Crucell 425
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 426
Cenix BioScience Enters Into Licensing Agreement With Janssen 427
Bioceros Expands Licensing Agreement With Crucell 428
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 429
Pepscan Therapeutics Enters Into Licensing Agreement With Crucell Holland 430
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 431
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 433
Tibotec Pharma Enters Into Licensing Agreement With Hetero Drugs For TMC278 434
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 436
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 437
Equity Offering 438
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 438
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 440
Achillion Pharma to Raise Funds through Secondary Offering of Shares 441
Alligator Bioscience Raises USD252.8 Million in IPO 442
Tesaro Raises USD50 Million in Private Placement of Shares 444
Achillion Pharma Raises USD225 Million in Private Placement of Shares 445
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 447
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 449
MacroGenics Raises USD75 Million in Private Placement of Common Stock 451
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 453
Debt Offering 454
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 454
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 456
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 458
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 459
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 461
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 463
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 465
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 467
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 469
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 471
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$300 Million 472
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2013 For US$500 Million 474
Johnson & Johnson Completes Public Offering Of 0.70% Senior Unsecured Notes Due 2013 For US$500 Million 476
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$900 Million 478
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$450 Million 480
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 482
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 484
Asset Transactions 486
HRA Pharma Acquires Compeed from Cilag 486
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 487
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 488
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 489
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 490
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 491
Vivus Acquires Topiramate Related Patents from Janssen Pharma 493
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 494
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 495
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 496
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 498
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 499
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 500
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 501
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 502
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 503
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 504
Insight Pharma Acquires MONISTAT Business In North America From McNEIL-PPC 505
Ilex Consumer Products Acquires St. Joseph’s Aspirin Brand From McNeil 506
Prestige Brands Completes Acquisition Of Dramamine Assets From McNeil-PPC 507
Acquisition 508
Johnson & Johnson Acquires Actelion for USD30 Billion 508
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 510
Ethicon Acquires Torax Medical 512
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 513
DePuy Orthopaedics Acquires BioMedical Enterprises 514
Johnson & Johnson Consumer to Acquire NeoStrata 515
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 516
Johnson and Johnson May Sell Noramco 517
Johnson & Johnson Acquires Novira Therapeutics 518
Biosense Webster Acquires Coherex Medical 519
Actelion Plans to Acquire ZS Pharma 520
Actelion Rejects Acquisition Offer from Shire 521
Janssen Pharma Acquires XO1 522
Valneva Acquires Crucell Sweden for USD54 Million 523
Tetraphase Pharma May Sell Itself 524
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 525
Cilag Acquires Covagen 527
Novartis Acquires CoStim Pharma 528
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 530
Johnson & Johnson Completes Acquisition Of Aragon Pharma For US$1 Billion 532
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 534
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 535
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 537
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 538
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 540
Janssen-Cilag Acquires CorImmun 541
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 543
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 544
SuperGen Completes Acquisition Of Astex Therapeutics 545
Johnson & Johnson Acquires Crucell 548
Johnson & Johnson – Key Competitors 550
Johnson & Johnson – Key Employees 551
Johnson & Johnson – Locations And Subsidiaries 553
Head Office 553
Other Locations & Subsidiaries 553
Recent Developments 571
Strategy And Business Planning 571
Apr 05, 2016: Johnson & Johnson Announces Launch of New Global Public Health Strategy at Opening of New Operations in Africa 571
Financial Announcements 573
Oct 17, 2017: Johnson & Johnson Reports 2017 Third-Quarter Results 573
Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 575
Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 577
Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 579
Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 581
Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 583
Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results 585
Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results 587
Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results 589
Corporate Communications 591
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with J

List of Tables
Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 22
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 23
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 24
Johnson & Johnson, Deals By Therapy Area, 2011 to YTD 2017 25
Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 27
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 29
Janssen Pharma Acquires CERC-501 from Cerecor 63
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 64
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 65
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 66
J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 67
On Target Laboratories Raises USD40 Million in Financing 69
Fusion Pharma Raises Additional USD17 Million in Series A Financing 70
XW Labs Raises USD17.5 Million in Series B Financing 72
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 73
E-scape Bio Raises Additional USD8 Million in Series A Financing 75
DayTwo Secures USD12 Million in Series A Funding 76
DayTwo Raises USD12 Million in Series A Financing 77
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 78
Biomx Raises USD24 Million in Series A Venture Financing 79
Pulmocide Raises USD30.4 Million in Series B Financing 80
Grail Raises USD914 Million in First Tranche of Series B Financing 82
Fusion Pharma Raises USD19 Million in Series A Financing 84
SuperX Raises USD11 Million in Series A Financing 85
Caelus Health Raises USD2.7 Million in Series A Financing 86
ApoGen Biotech Raises USD7 Million in Series A Financing 87
ReVision Optics Raises USD32 Million in Venture Financing 88
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 90
V-Wave Raises USD28 Million in Venture Financing 91
Lodo Therapeutics Raises USD17 Million in Series A Financing 92
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 94
Petra Pharma Raises USD48 Million in Series A Financing 95
Protekt Therapeutics Raises More Than USD2 Million in Financing 97
Navitor Pharma Raises USD33 Million in Series B Financing 98
First Aid Shot Therapy Raises USD24 Million in Series C Financing 100
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 101
Asceneuron Raises USD30.6 Million in Series A Financing 102
Merus Raises USD46.4 Million in First Tranche of Series C Financing 104
E-scape Bio Raises USD55 Million in Series A Financing 106
Alligator Bioscience to Raise Funds through Venture Financing 107
Protagonist Therapeutics Raises USD40 Million in Series C Financing 108
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 110
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 112
La Lumiere Raises USD20 Million in Series B Venture Financing 113
Tetra Discovery Raises Funds through Venture Financing 114
XW Labs Raises USD5.5 Million in Series A Financing 115
Inivata Raises USD6.5 Million in Venture Financing 116
Inviata Raises USD6.5 Million in Venture Financing 117
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 118
Ascelegen Therapeutics Raises Funds through Venture Financing 119
Padlock Therapeutics Raises Funds through Series A Financing 120
Navitor Pharma Raises USD24 Million in Series A Financing 121
Aduro BioTech Raises USD55 Million in Series C Financing 123
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 124
Assembly Pharma Raises Funds Through Seed Financing 125
Alios BioPharma Raises US$41 Million In Series B Venture Financing 126
Covagen Raises US$50.3 Million In Series B Financing 127
Novira Therapeutics Raises US$28 Million In Series A Financing 129
SutroVax Raises Funds Through Initial Financing Round 131
TopiVert Raises USD28 Million in Venture Financing 132
TopiVert Raises US$7.4 Million In Venture Financing 133
Pulmocide Raises US$27.4 Million In Series A Financing 135
Biocartis Raises US$40.5 Million In Series E Financing 137
Merus Raises US$42 Million In Extended Series B Financing 139
Rodin Therapeutics Raises Funds Through Seed Financing 141
Vedanta Biosciences Raises Funds Through Venture Financing 142
XO1 Raises USD11 Million in Venture Financing 143
X01 Raises US$11 Million In Series A Financing 144
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 145
Novira Therapeutics Secures USD25 Million in Venture Funding 147
Aquinox Pharma Raises US$18 Million In Series C Financing 148
Biocartis Raises US$44.7 Million In Series D Financing 149
Genocea Biosciences Raises US$30 Million In Series C Financing 151
Aragon Pharma Raises US$50 Million In Series D Financing 153
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 154
Celladon Raises Additional US$10 Million In Series D Financing 156
Direct Flow Medical Secures USD0.28 Million in Venture Funding 158
Coherex Medical Secures USD16.5 Million in Venture Funding 159
Aragon Pharma Raises US$42 Million In Series C Financing 160
Biocartis Secures US$96 Million In Series C Financing Round 161
Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 163
Spinal Modulation Secures US$30 Million In Series D Financing 164
23andMe Raises Additional USD9 Million in Series C Financing 166
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 167
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 169
Water Street Healthcare Partners Acquires OraPharma 170
Janssen Amends Licensing Agreement with Gilead for STR 171
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 172
Genomic Health Enters into Research Agreement with Janssen Pharma 173
BioMed X Enters into Agreement with Janssen Research & Development 174
Cerveau Technologies Enters into Agreement with Janssen Pharma 175
Janssen Research & Development Enters into Agreement with U.S. Department of Health 176
Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 177
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 178
Proteros biostructures Enters into Research Agreement with Janssen Biotech 179
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 180
Idorsia and Janssen Biotech to Enter into option Agreement 181
Monash University Enters into Research Agreement with Janssen Biotech 182
Phagelux Enters into Agreement with Johnson & Johnson Consumer 183
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 184
PeptiDream Enters into Agreement with Janssen Pharma 185
Janssen Pharma Enters into Partnership with Premier 186
Renova Therapeutics Enters into Agreement with Janssen Pharma 187
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 188
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 189
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 190
Janssen Research & Development Enters into Agreement with ChemDiv 191
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 192
Enamine Expands Agreement with Actelion 193
Karolinska Institutet Partners with Johnson & Johnson Companies 194
Janssen Biotech Enters into Partnership with Bristol-Myers 195
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 196
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 197
Janssen Pharma Enters into Partnership with Bird Rock Bio 198
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 199
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 200
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 201
HitGen Enters into Agreement with Janssen Biotech 202
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 203
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 204
Philogen Enters into Co-Development Agreement with Janssen Biotech 205
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 206
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 207
Amyris Enters into Research Agreement with Janssen Biotech 208
Janssen Research & Development Enters into Agreement with Genentech 209
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 210
DiamiR Enters into Research Agreement with Janssen Pharma 211
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 212
Janssen Biotech Enters into Agreement with HUB foundation 213
Janssen Pharma Enters into Agreement with University of Pennsylvania 214
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 215
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 216
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 217
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 218
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 219
Janssen Pharma Enters into Agreement with University of California, San Diego 220
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 221
Johnson & Johnson Consumer Enters into Agreement with BioMed X 222
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 223
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 224
Janssen Biotech Enters into Agreement with Eureka Therapeutics 225
Intrexon Enters into Research Agreement with Janssen Pharma 226
Cypralis Enters into Research Agreement with Janssen Pharma 227
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 228
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 229
SynAging Extends Agreement with Actelion Pharma 230
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 231
Nuevolution Enters into Discovery Agreement with Janssen Biotech 232
enGene Enters into Agreement with Janssen Biotech 233
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 234
BlinkBio Enters into Discovery Agreement with Janssen Pharma 235
UbiVac Enters into Agreement with Janssen Biotech 236
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 237
Nextera Enters into Research Agreement with Janssen Biotech 238
Handok Enters into Agreement with Actelion Pharmaceuticals 239
Actelion Forms Joint Venture with Max Planck Society 240
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 241
Janssen Cilag Enters into Agreement with UniQuest 242
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 243
Janssen Biotech Enters into Research Agreement with Emulate 244
Johnson & Johnson Innovation Partners with Lead Discovery Center 245
NeurOp Enters into Research Agreement with Janssen Pharma 246
AC Immune Enters into Research Agreement with Janssen Pharma 247
X-Chem Expands Agreement with Janssen Biotech 248
Vectura Enters into Development and License Agreement with Janssen Biotech 249
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 250
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 251
Atreca Enters into Research Agreement with Janssen Biotech 252
Vaccinex Enters into Research Agreement with Janssen Research & Development 253
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 254
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 255
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 256
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 257
Alector Enters Into Research Agreement With Janssen Pharma 258
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 259
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 260
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 261
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 262
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 263
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 264
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 265
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 266
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 267
Open Monoclonal Expands Agreement with CNA Development 268
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 269
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 270
ex scientia Enters into Agreement with Janssen Research & Development 272
Mellitech Enters into Agreement with Janssen Pharma 273
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 274
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 275
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 276
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 277
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 278
Beactica Enters Into Research Agreement With Janssen Research & Development 279
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 280
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 281
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 282
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 283
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 284
Dendright Enters Into Research Agreement With Janssen-Cilag 285
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 286
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 287
Molecular Partners Enters Into Research Agreement With Janssen Biotech 288
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 289
Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 290
Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 291
Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 292
ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 293
Synthes Enters Into Co-Development Agreement With Eli Lilly 294
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 295
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 296
Beactica Enters Into An Agreement With Janssen 297
Merck Amends Distribution Agreement With Johnson & Johnson 298
Medivir Enters Into Collaboration With Janssen Pharmaceutica 300
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 301
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 302
Stereotaxis Amends Co-Development Agreement With Biosense Webster 303
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 304
Janssen Biotech Enters into Licensing Agreement with Zymeworks 305
Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 306
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 307
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 309
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 310
Pulmatrix Enters into Licensing Agreement with RespiVert 311
Janssen Biotech Enters into Licensing Agreement with Trianni 312
Janssen Biotech Enters into Licensing Agreement with Ablexis 313
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 314
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 316
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 317
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 318
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 319
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 320
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 321
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 322
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 324
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 325
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 326
Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015 327
Janssen Biotech Enters into Licensing agreement with Tesaro 328
ViaCyte Enters into Licensing Agreement with Janssen Biotech 329
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 330
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 331
Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 332
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 333
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 334
AC Immune Enters into Licensing Agreement with Janssen Pharma 335
Janssen Expands Licensing Agreement with Gilead 336
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 337
Kura Oncology Amends Licensing Agreement with Janssen Pharma 339
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 341
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 342
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 344
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 345
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 347
XO1 Enters into Licensing Agreement with Cambridge Enterprise 348
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 349
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 350
Depomed Enters Into Licensing Agreement With Janssen Pharma 352
Genmab Expands Licensing Agreement With Janssen Biotech 353
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 354
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 355
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 356
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 357
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 358
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 359
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 360
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 361
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 362
Poseida Therapeutics Enters into Licensing Agreement with Janssen 363
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 364
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 365
Gour Medical Enters into Licensing Agreement with Actelion Pharma 366
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 367
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 368
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 369
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 370
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 371
AB-Biotics Enters into Licensing Agreement with Cilag 372
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 373
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 374
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 375
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 376
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 377
Janssen Pharma Enters into Licensing Agreement with BiocerOX 379
Orion Enters Into Licensing Agreement With Janssen Pharma 380
CSL Enters Into Licensing Agreement With Janssen For CSL-362 381
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 382
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 384
Intravacc Enters into Licensing Agreement with Crucell Holland 385
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 386
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 387
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 388
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 389
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 390
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 391
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 392
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 393
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 394
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 395
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 396
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 397
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 398
Shionogi Enters Into Licensing Agreement With Janssen Pharma 400
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 401
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 403
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 404
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 405
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 407
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 408
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 410
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 411
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 412
GlaxoSmithKline Enters into Licensing Agreement with Janssen Biologics 413
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 414
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 415
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 416
Topivert Enters into Licensing Agreement with RespiVert 418
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 419
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 420
Alios BioPharma Enters Into Licensing Agreement With Versitech 421
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 422
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 423
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 424
Isconova Expands Licensing Agreement With Crucell 425
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 426
Cenix BioScience Enters Into Licensing Agreement With Janssen 427
Bioceros Expands Licensing Agreement With Crucell 428
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 429
Pepscan Therapeutics Enters Into Licensing Agreement With Crucell Holland 430
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 431
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 433
Tibotec Pharma Enters Into Licensing Agreement With Hetero Drugs For TMC278 434
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 436
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 437
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 438
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 440
Achillion Pharma to Raise Funds through Secondary Offering of Shares 441
Alligator Bioscience Raises USD252.8 Million in IPO 442
Tesaro Raises USD50 Million in Private Placement of Shares 444
Achillion Pharma Raises USD225 Million in Private Placement of Shares 445
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 447
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 449
MacroGenics Raises USD75 Million in Private Placement of Common Stock 451
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 453
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 454
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 456
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 458
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 459
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 461
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 463
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 465
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 467
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 469
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 471
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$300 Million 472
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2013 For US$500 Million 474
Johnson & Johnson Completes Public Offering Of 0.70% Senior Unsecured Notes Due 2013 For US$500 Million 476
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$900 Million 478
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$450 Million 480
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 482
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 484
HRA Pharma Acquires Compeed from Cilag 486
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 487
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 488
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 489
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 490
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 491
Vivus Acquires Topiramate Related Patents from Janssen Pharma 493
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 494
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 495
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 496
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 498
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 499
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 500
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 501
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 502
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 503
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 504
Insight Pharma Acquires MONISTAT Business In North America From McNEIL-PPC 505
Ilex Consumer Products Acquires St. Joseph's Aspirin Brand From McNeil 506
Prestige Brands Completes Acquisition Of Dramamine Assets From McNeil-PPC 507
Johnson & Johnson Acquires Actelion for USD30 Billion 508
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 510
Ethicon Acquires Torax Medical 512
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 513
DePuy Orthopaedics Acquires BioMedical Enterprises 514
Johnson & Johnson Consumer to Acquire NeoStrata 515
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 516
Johnson and Johnson May Sell Noramco 517
Johnson & Johnson Acquires Novira Therapeutics 518
Biosense Webster Acquires Coherex Medical 519
Actelion Plans to Acquire ZS Pharma 520
Actelion Rejects Acquisition Offer from Shire 521
Janssen Pharma Acquires XO1 522
Valneva Acquires Crucell Sweden for USD54 Million 523
Tetraphase Pharma May Sell Itself 524
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 525
Cilag Acquires Covagen 527
Novartis Acquires CoStim Pharma 528
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 530
Johnson & Johnson Completes Acquisition Of Aragon Pharma For US$1 Billion 532
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 534
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 535
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 537
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 538
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 540
Janssen-Cilag Acquires CorImmun 541
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 543
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 544
SuperGen Completes Acquisition Of Astex Therapeutics 545
Johnson & Johnson Acquires Crucell 548
Johnson & Johnson, Key Competitors 550
Johnson & Johnson, Key Employees 551
Johnson & Johnson, Subsidiaries 553

★海外企業調査レポート[Johnson & Johnson (JNJ)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Capricor Therapeutics Inc (CAPR)：企業の財務・戦略的SWOT分析
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Tanzania Electric Supply Co Ltd：企業の戦略的SWOT分析
    Tanzania Electric Supply Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • ScinoPharm Taiwan Ltd (1789)：製薬・医療：M&Aディール及び事業提携情報
    Summary ScinoPharm Taiwan Ltd (ScinoPharm) provides process research and development (R&D) and active pharmaceutical ingredient (API) manufacturing services to the pharmaceutical industry. It services include custom synthesis for early phase pharmaceutical activities, brand companies and APIs for th …
  • Verona Pharma Plc (VRP)：医療機器：M&Aディール及び事業提携情報
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Takaful Emarat – Insurnace (P.S.C)：企業の戦略・SWOT・財務情報
    Takaful Emarat - Insurnace (P.S.C) - Strategy, SWOT and Corporate Finance Report Summary Takaful Emarat - Insurnace (P.S.C) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Eloro Resources Ltd (ELO)：企業の財務・戦略的SWOT分析
    Summary Eloro Resources Ltd (Eloro Resources) is a mining and minerals exploration and development company that offers mineral exploration and development services. The company acquires, explores and develops precious and base-metal resources properties across Quebec. It explores for titanium, silve …
  • Rocky Brands Inc (RCKY)：企業の財務・戦略的SWOT分析
    Rocky Brands Inc (RCKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Service Corporation International (SCI)：企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Insurance Australia Group Limited：企業の戦略・SWOT・財務情報
    Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report Summary Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • National Health Insurance Company – Daman PJSC：企業の戦略・SWOT・財務情報
    National Health Insurance Company - Daman PJSC - Strategy, SWOT and Corporate Finance Report Summary National Health Insurance Company - Daman PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Gammon Construction Ltd：企業の戦略的SWOT分析
    Gammon Construction Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • E.ON SE (EOAN)-エネルギー分野：企業M&A・提携分析
    Summary E.ON SE (E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports, and supplies gas and conducts trading, carbon sourcing, and electricity and gas distribution. It generates power from diverse fuel sources including wind, hydro, nuclear, coal, na …
  • Lear Corporation：企業の戦略・SWOT・財務情報
    Lear Corporation - Strategy, SWOT and Corporate Finance Report Summary Lear Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nanjing Pharmaceutical Co Ltd (600713)：企業の財務・戦略的SWOT分析
    Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Strike Energy Ltd (STX)：企業の財務・戦略的SWOT分析
    Summary Strike Energy Ltd (Strike Energy) is an oil and gas exploration and development company that explores, produces, and develops shale oil and gas. The company provides properties such as Eagle Ford Shale, Permian Basin, Cooper Basin, gulf coast conventional, and others. It has exploration and …
  • Koch Enterprises, Inc.：企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • OK Biotech Co Ltd (4155)：医療機器：M&Aディール及び事業提携情報
    Summary OK Biotech Co Ltd (OK Biotech) is a medical device manufacturing and distribution company that manufactures and distributes blood glucose monitoring devices and homecare medical products, among others. The company’s blood glucose monitoring devices include blood glucose meter systems, blood …
  • PT. Indonesia Power：企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • South Texas Accelerated Research Therapeutics：製薬・医療：M&Aディール及び事業提携情報
    Summary South Texas Accelerated Research Therapeutics (START) accelerates the development of novel anticancer agents that improves personalized and clinical care for cancer patients. The company offers preclinical and clinical research services which include pharmacokinetics, in vivo and in vitro se …
  • TMC Life Sciences Berhad (TMCLIFE)：製薬・医療：M&Aディール及び事業提携情報
    Summary TMC Life Sciences Berhad (TMC Life) is a healthcare service provider that offers medical care services. The center operates through Thomson Hospital and TMC Fertility Center. Its services include breast and endocrine surgery, general surgery, clinical laboratory services, daycare, dietetic s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆